Similar articles

• Optimizing end points and outcomes in cancer-associated wasting.

  Dahele M, Wall L. Dahele M, et al. J Clin Oncol. 2005 Apr 20;23(12):2871-2; author reply 2872-3. doi: 10.1200/JCO.2005.05.269. J Clin Oncol. 2005. PMID: 15838010 No abstract available.
• An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort.

  Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Mailliard JA, Bushey TI, Nair S, Christensen B; North Central Cancer Treatment Group. Jatoi A, et al. J Clin Oncol. 2004 Jun 15;22(12):2469-76. doi: 10.1200/JCO.2004.06.024. J Clin Oncol. 2004. PMID: 15197210 Clinical Trial.
• [Croatian guidelines for use of eicosapentaenoic acid and megestrol acetate in cancer cachexia syndrome].

  Krznarić Z, Juretić A, Samija M, Dintinjana RD, Vrdoljak E, Samarzija M, Kolacek S, Vrbanec D, Prgomet D, Ivkić M, Zelić M; Croatian Society of Parenteral and Enteral Nutrition, Croation Society of Oncology, Croation society of Medical Oncology, Croation Medical Association. Krznarić Z, et al. Lijec Vjesn. 2007 Dec;129(12):381-6. Lijec Vjesn. 2007. PMID: 18383739 Croatian.
• Pharmacological therapeutics in nutritional management.

  Elovic E. Elovic E. J Head Trauma Rehabil. 2000 Jun;15(3):962-4. doi: 10.1097/00001199-200006000-00009. J Head Trauma Rehabil. 2000. PMID: 10785626 Review. No abstract available.
• Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients.

  Mateen F, Jatoi A. Mateen F, et al. Clin Nutr. 2006 Oct;25(5):711-5. doi: 10.1016/j.clnu.2006.05.009. Epub 2006 Jul 25. Clin Nutr. 2006. PMID: 16867306 Review.